The trials compared a pharmacologic analgesic versus an alternative analgesic or placebo. Twenty-five trials enrolled participants with musculoskeletal pain, six with otorhinolaryngologic pain ...
The US Food and Drug Administration has approved the use of a novel painkiller as an effective treatment for short-term ...
Today, the U.S. Food and Drug Administration (FDA) gave its approval to Vertex Pharmaceuticals' (NASDAQ: NASDAQ:VRTX) ...
Dr. Sanjay Gupta said Tuesday that the approval of a new non-opioid pain medication is “a pretty big deal.” “This is a pretty ...
The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...
Suzetrigine selectively inhibits the NaV1.8 pain-signaling pathway in the peripheral nervous system and provides effective ...
The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class ...
African American patients are less likely than White patients to receive comprehensive pain treatment post- noncardiac ...
Analyst is bullish on Vertex Pharmaceuticals, citing FDA approval for JOURNAVX and strong earnings growth potential in 2025.
The FDA has approved Journavx 50 mg oral tablets for the treatment of moderate to severe acute pain in adults, according to a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback